This clinical trial is focused on studying the effects of a treatment called Efruxifermin on a liver condition known as Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH). These conditions are types of liver disease that occur when fat builds up in the liver, leading to inflammation and damage. The study aims to evaluate how well Efruxifermin works in people with a specific stage of liver disease called compensated cirrhosis, which means the liver is scarred but still able to perform its functions.
Participants in the study will receive either Efruxifermin or a placebo, which is a substance with no active medication. The treatment is given as a solution for injection under the skin. The study will monitor participants over a period to see if Efruxifermin can improve liver health by reducing scarring and preventing the disease from getting worse. The main goal is to see if the treatment can help people live longer without experiencing serious liver-related problems.
The study will last for several years, with regular check-ups to assess the health of the liver and overall well-being of the participants. The researchers will look at various health markers, including liver function tests and other indicators of liver health, to determine the effectiveness of Efruxifermin compared to the placebo. This research is important for understanding how to better treat liver diseases like NASH and MASH and improve the quality of life for those affected.
Belgium 
Denmark 
France 
Germany 
Greece 
Italy 
Poland 
Spain